Sentinel Lymph Node Biopsy in Breast Cancer

Chatterjee, Abhishek; Serniak, Nicholas; Czerniecki, Brian J.

doi:10.1097/ppo.0000000000000090

Cited by 38 publications

(28 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has the potential to improve the accuracy of axillary staging while reducing the number of unnecessary axillary dissection and decreasing morbidity. The safety of the sentinel lymph node biopsy was underscored by the NSABP B-32 trial which showed that overall survival (OS), disease free survival (DFS) and regional control (RC) were statistically equal between the sentinel lymph node and standard axillary node dissection when the node was negative (18).…”

Section: Discussionmentioning

confidence: 99%

Prognostic Factors of Treatment Failure for Early Breast Cancer after Breast Conserving Surgery

Aldaqaf¹,

Brătucu²

2018

chr

View full text Add to dashboard Cite

RezumatIntroducere: Cancerul de sân este cel mai frecvent tip de cancer la femeile din ţările occidentale dezvoltate şi devine şi mai semnificativ în multe ţări în curs de dezvoltare. Chirurgia de conservare a sânilor a devenit standardul de aur pentru pacienţii cu cancer de sân (stadiul I, II) cu cancer de sân timpuriu, cu o selecţie adecvată a pacienţilor. Factori de risc importanţi pentru eşecul tratamentului, includ starea marginilor de rezecţie, vârsta, multicentricitatea tumorii şi utilizarea radioterapiei şi a terapiei hormonale adjuvante. Scopul: Stabilirea variabilelor de prognostic pentru recidiva tumorilor mamare ipsilaterale în cancer de sân incipient după chirurgia conservatoare de sân şi rata de supravieţuire. Materiale şi metodă: Am analizat 100 de paciente cu cancer de sân incipient care au suferit chirurgie de conservare a sânilor. Datele au fost analizate pentru eşecul tratamentului; analiza a fost efectuată prin test Chi-pătrat (χ 2 ), regresie multivariată Cox şi Kaplan Maier pentru analiza supravieţuirii. Rezultate: 100 de pacienţi au suferit chirurgie de conservare a sânilor pentru cancer de sân incipient. Au fost 75% dintre pacienţii cu vârsta peste 40 de ani. Tumorile T2 au fost observate la 87% dintre pacienţi şi la 53% dintre pacienţi au fost implicaţi noduli. Modelul de recurenţă a fost de 14%; Pe analiza multivariată, gradul şi marja tumorilor au fost corelate cu supravieţuirea locală fără boală. Supravieţuirea fără boală locală la 3 ani şi supravieţuirea globală a fost de 86% şi, respectiv, 97%. Results: 100 female patients underwent BCS for EBC. There were 75% of patients above 40 years old. T2 tumours were observed in 87% of patients and 53% patients had nodal involvement. There was a pattern of recurrence of 14%; Using the multivariate analysis tumour grade and margin were correlated to local disease free survival. The 3 years local disease free survival and overall survival was of 86 % and 97% respectively. Conclusion: Breast conservative surgery is a highly accepted surgery for early breast cancer with good result. Tumour grade and margin were correlated to local disease free survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic Factors of Treatment Failure for Early Breast Cancer after Breast Conserving Surgery

Aldaqaf¹,

Brătucu²

2018

chr

View full text Add to dashboard Cite

show abstract

“…The sentinel lymph node is the first site of lymphatic spread of malignant disease and predicts the status of the remaining lymph node basin . In man, sentinel lymph node biopsy is now considered the standard of care in evaluating metastatic spread to the axillary lymph node chain in women with breast cancer because of its minimally invasive nature, low false negative rate (5%‐10%), and high sensitivity rate (90%‐95%) . Sentinel lymph node mapping has also been evaluated with success in people with oral tumors .…”

Section: Discussionmentioning

confidence: 99%

“…11 In man, sentinel lymph node biopsy is now considered the standard of care in evaluating metastatic spread to the axillary lymph node chain in women with breast cancer because of its minimally invasive nature, low false negative rate (5%-10%), and high sensitivity rate (90%-95%). 15,16 Sentinel lymph node mapping has also been evaluated with success in people with oral tumors. 17 Because of the aberrant lymphatic drainage seen in dogs with metastatic oral tumors, 18 sentinel lymph node mapping aids in identifying which lymph node to biopsy or remove to avoid unnecessary dissection and associated morbidity.…”

Section: Discussionmentioning

confidence: 99%

Ventral cervical versus bilateral lateral approach for extirpation of mandibular and medial retropharyngeal lymph nodes in dogs

2018

View full text Add to dashboard Cite

show abstract

“…[10–14] Finally, the approach to pathology evaluation based on sentinel nodes has become much more uniform, including the collection and processing of specimens. [15] Taken together, these advances appear to have markedly limited individual oncologists’ influence on variation in chemotherapy use in the community. These findings should reassure patients because they suggest that oncologists are uniformly applying, evidence-based clinical algorithms to guide breast cancer treatment decisions.…”

Section: Discussionmentioning

confidence: 99%

Oncologists’ influence on receipt of adjuvant chemotherapy: does it matter whom you see for treatment of curable breast cancer?

Hawley

Bondarenko

Jagsi

et al. 2017

Breast Cancer Res Treat

View full text Add to dashboard Cite

Purpose We know little about whether it matters which oncologist a breast cancer patient sees with regard to receipt of chemotherapy. We examined oncologists’ influence on use of recurrence score (RS) testing and chemotherapy in the community. Methods We identified 7,810 women with stages 0-II breast cancer treated in 2013–15 through the SEER registries of Georgia and Los Angeles County. Surveys were sent 2 months post-surgery, (70% response rate, n=5,080). Patients identified their oncologists (n=504) of whom 304 responded to surveys (60%). We conducted multi-level analyses on patients with ER positive HER2 negative invasive disease (N=2973) to examine oncologists’ influence on variation in RS testing and chemotherapy receipt, using patient and oncologist survey responses merged to SEER data. Results Half of patients (52.8%) received RS testing and 27.7% chemotherapy. One-third (35.9%) of oncologists treated >50 new breast cancer patients annually; mean years in practice was 15.8. Oncologists explained 17% of the variation in RS testing but little of the variation in chemotherapy receipt (3%) controlling for clinical factors. Patients seeing an oncologist who was one standard deviation above the mean use of RS testing had over two-times higher odds of receiving RS (2.47, 95% CI 1.47–4.15), but a parallel estimate of the association of oncologist with the odds of receiving chemotherapy was much smaller (1.39, CI 1.03–1.88). Conclusions Clinical algorithms have markedly reduced variation in chemotherapy use across oncologists. Oncologists’ large influence on variation in RS use suggests that they variably seek tumor profiling to inform treatment decisions.

show abstract

Sentinel Lymph Node Biopsy in Breast Cancer

Cited by 38 publications

References 43 publications

Prognostic Factors of Treatment Failure for Early Breast Cancer after Breast Conserving Surgery

Prognostic Factors of Treatment Failure for Early Breast Cancer after Breast Conserving Surgery

Ventral cervical versus bilateral lateral approach for extirpation of mandibular and medial retropharyngeal lymph nodes in dogs

Oncologists’ influence on receipt of adjuvant chemotherapy: does it matter whom you see for treatment of curable breast cancer?

Contact Info

Product

Resources

About